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ABSTRACT 
 
DAX-1 (NR0B1) is an orphan nuclear receptor that plays a key role in the development and 
maintenance of steroidogenic tissue in mammals.  Dax-1 is also expressed in mouse embryonic 
stem (ES) cells and is required to maintain pluripotency.  Duplication of the X-chromosome in 
the region containing the NR0B1 gene results in sex reversal, and mutations in NR0B1 cause 
adrenal hypoplasia congenita.  DAX-1 has been observed to act as a corepressor of other nuclear 
receptors including androgen receptor (AR), estrogen receptor (ER), and steroidogenic factor 1 
(SF-1).  In addition to pluripotent ES cells, DAX-1 is primarily expressed in select tissues of the 
body such as testes, ovaries, adrenal cortex and breast.  In some cases, changes in DAX-1 
expression may serve as an indicator of aberrant growth.  For example, DAX-1 expression is 
greatly reduced in ER+ breast cancer patient samples and several ER+ cell lines; however the 
mechanism leading to this change in DAX-1 expression is unknown.  Here, we propose that 
expression of DAX-1 may be governed by epigenetic mechanisms.   
We sought to determine whether promoter region CpG island methylation and expression of 
DAX-1 were inversely related , and if the loss of DAX-1 expression in the breast cancer cell line 
MCF-7 is due to epigenetic mechanisms. Using gene expression assays and bisulfite sequencing, 
we have confirmed the relationship between methylation status and DAX-1 expression in MCF7 
and A549 cancer cell lines.  We have further analyzed the DAX-1 CpG island to observe the 
presence of epigenetic readers MeCP2 and MBD1 that link methylation to gene repression, 
suggesting DAX-1 is expressed and regulated differentially by epigenetic mechanisms in the 
cancer cell lines MCF7 and A549. 
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CHAPTER 1: INTRODUCTION 
 
Nuclear  Receptors 
Nuclear Receptors (NRs) are a large group of transcription factors that are characterized by their 
ability to bind steroid hormones and other lipophilic non-steroid hormones and regulate gene 
expression by directly binding to the promoter and regulatory regions of specific target genes
1 
(Fig. 1-1).  Nuclear receptors play a major role in differential gene expression and are found in 
diverse animal species from invertebrates to primates
2
.  Evidence suggests that nuclear receptors 
may have first appeared  around the same time animals appeared in the fossil record, 
approximately 635 million years ago
2
.  There exists a loose correlation between the number and 
complexity of tissue types and the number of NR genes an organism has, ranging from only a 
few NR genes in sponges to 48 distinct NR genes in humans.  In humans, these 48 receptors of 
varied structure and function comprise the nuclear receptor superfamily.  Nuclear receptor 
ligands include steroid hormones such as estrogen and testosterone, Vitamin A compounds 
known as retinoids, tyrosine-based hormones known as thyroid hormones, and Vitamin D3 
2
.   
Many nuclear receptors have no known ligand, named orphan receptors, and have a reduced or 
non-existent ligand binding pocket
3
.  Orphan receptors are found in every metazoan species, and 
have diverse functions that do not require initiation by ligand binding.
3
.  All vertebrate orphan 
nuclear hormone receptors contain ligand binding domains (LBDs).  However, the LBDs of 
orphan nuclear receptors mediate multiple other functions besides ligand binding such as 
dimerization and coactivator interaction, allowing the orphan receptors to regulate gene 
expression and endocrine responses without direct binding of a ligand.   
10 
 
 
Figure 1-1.  A typical nuclear receptor binds a hormone ligand, dissociates heat shock proteins, 
homodimerizes, then translocates to the nucleus where it directly binds to a hormone response 
elementon the DNA in association with coactivators and RNA polymerase to affect the levels of 
gene expression.  Created by Boghog2. Nuclear_receptor_action. Accessed 9/10/2014 at 
http://upload.wikimedia.org/wikipedia/commons/3/3f/Nuclear_receptor_action.png 
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Nuclear receptors were first discovered to have modular substructures by Wrange et al  in 19784. 
Since then, the structure of nuclear hormone receptors has been elucidated.  A typical nuclear 
receptor contains an N-terminal domain of varied function, a zinc finger DNA binding domain 
(DBD) that is important in mediating direct contact to the DNA, a flexible hinge region, a ligand 
binding domain (LBD) containing a ligand binding pocket, and a C-terminal domain
5
 (Fig. 1-2).  
Nuclear receptors are responsible for a wide variety of physiological functions including cell 
growth and differentiation, fatty acid synthesis, and cancer initiation and progression
6,7,8
.   
During mammalian development, estrogen receptor (ER) is expressed in reproductive tissue and 
upon binding to estrogens stimulates cell proliferation by activating transcription of cyclins
6
.   In 
stem cells, orphan nuclear receptors such as LRH-1, SF-1, and DAX-1 play an important role for 
the maintenance of pluripotency
7
.  In lipid metabolism, the orphan receptor liver X receptor 
(LXR) regulates key genes in cholesterol and fatty acid pathways including fatty acid synthase 
(FAS), and sterol regulatory element binding protein 1c 
8
.  Nuclear receptors are especially 
intriguing to biologists because they combine the function of receptors, which are typically 
membrane-bound, and transcription factors into a modular protein that can affect gene 
expression without the need for a long cascade of signal transduction.   
Nuclear receptor mechanism of action 
Nuclear receptor function is divided into several mechanistic classes.  Type I nuclear receptors 
bind ligands in the cytosol, homodimerize, and are actively transported to the nucleus where they 
bind to sequence specific regions of the DNA known as hormone response elements (HREs)
9
.  
Type I nuclear receptors bind to HREs that contain two sequence specific binding recognition 
half-sites that are inverted and separated by a variable region.  Type II receptors maintain their  
12 
 
 
 
Figure 1-2.  The structure of a typical nuclear receptor including the N-terminal region, DNA 
binding domain (DBD), flexible hinge region, and ligand binding domain (LBD). 
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presence in the nucleus at all times and form heterodimers with other nuclear receptors, most 
commonly partnered with retinoid X receptor (RXR)
10
(Fig. 1-3).  Type III receptors are similar 
to type I receptors in mode of action except they bind to HREs with direct repeats instead of 
inverted repeats
1
.  Type IV nuclear receptors distinguish themselves by only binding to a single 
half-site in the target gene HRE
1
.  In most cases, nuclear receptors do not act alone and instead 
form a complex including coactivator and corepressor proteins
11
. 
Nuclear receptor coregulators 
Biochemical and proteomic analyses has shown that nuclear receptors do not act alone.  Nuclear  
receptor coregulators are  proteins that form protein-protein interactions to make large complexes 
with NRs on and off the DNA
11
.  A survey of the literature finds over 450 reported NHR 
coregulator species
12
.  Coregulators typically belong to one of two subgroups; coactivators or 
corepressors.  Coactivators are generally defined as molecules that are found bound with ligand-
activated NRs and lead to an increase in target gene expression
12
.  Corepressors are typically 
found bound to unliganded NRs and decrease target gene expression. Collectively, nuclear 
receptor coregulators, or SRCs (steroid hormone coregulators), share a conserved basic helix-
loop-helix that allows interaction with other coregulators and transcription factors and contains a 
nuclear localization signal
13
. In the N-terminal region is a leucine rich (LxxLL) domain that 
facilitates binding to NRs. SRCs play a role in regulating many aspects of gene regulation 
including transcription, cofactor recruitment, and post translational modifications
13
. SRC activity 
can be regulated by phosphorylation of specific residues of the SRC proteins themselves
13
.  
Nuclear receptor coactivators were originally found in complex with nuclear hormone receptors 
bound to nuclear DNA and are required for optimal activation of a ligand-bound nuclear 
hormone receptor
12,13
. Originally hypothesized to be a small family of simple “adapter” 
14 
 
 
 
 
 
 
 
 
 
 
Figure 1-3.  Activated Liver X Receptor (LXR) is bound by oxysterol ligand, homodimerized 
with Retinoid X Receptor (RXR) and bound to coactivators.  The complex recognizes the LXR 
response element AGGTCA xxxx AGGTCA on key genes in lipid metabolism pathways. RXR is 
a common heterodimerization partner for many type II nuclear receptors.  
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molecules, NR coactivators may be hundreds in number, and contribute to cancer biology and 
regulation of metabolism
12,13
.  Nuclear receptor corepressors are also important for regulating 
healthy levels of hormone responsive genes .  The two founding members of the corepressor 
class SMRT and N-CoR were discovered in relation with thyroid hormone resistance
14
, a rare 
syndrome where some or all of the body's tissues are resistant to the normal effects of thyroid 
hormone.  Point mutations in SMRT or N-CoR cause ligand-activated thyroid hormone receptor 
to be unable to release these corepressors, resulting in a continuously inactive receptor and a host 
of medical complications such as goiter and tachycardia
14
.  Expression levels of NHR 
coactivators also appear to be a critical factor in NR function.  Notable pathology related to NR 
coactivator dysfunction includes several types of cancers caused by overexpression of hormone-
regulated genes due to coactivator overexpression
14
.   
DAX-1 
First identified in association with X-linked adrenal hypoplasia
15
 (AHC) and dosage sensitive sex 
reversal (DSS)
16
, DAX-1 is classified as an orphan nuclear receptor, as no ligand has been 
identified to date
17
.  DAX-1 gene mutations are responsible for adrenal hypoplasia congenita, 
and duplications in the DAX-1 containing p21 region of the X-chromosome produce a phenotype 
of an XY female
15,16
.  Further study of the DAX-1 gene and 470aa protein reveals the absence of 
a typical NR zinc finger DNA binding motif and presence of a three times repeated leucine-rich 
motif (LXXLL) in the N-terminal region, similar to the so-called NR-box of known nuclear 
receptor co-regulators (Fig. 1-4)
17
.  DAX-1 is conserved throughout many animal species
2
. 
Alignment of the human and Mus musculus DAX-1 protein sequence demonstrates a moderate 
level of conservation over the entire protein (66% identity, Fig. 1-5) .   DAX-1 is primarily 
expressed along the hypothalamic-pituitary-adrenal/gonadal axis (HPA-axis), sharing a similar  
16 
 
 
Figure 1-4.  DAX-1 structure contains three LXXLL repeats and lacks a zinc finger DNA 
binding domain. DAX-1 contains a ligand binding domain, however no ligand has been 
identified, classifying DAX-1 as an orphan nuclear receptor. 
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Figure 1-5. The DAX-1 amino acid sequence shares 66% identity between mouse and human 
proteins.   
An * (asterisk) indicates an identical amino acid sequence.  A : (colon) indicates conservation between 
strongly similar groups. A . (period) indicates conservation between weakly similar groups.   
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expression pattern with steroidogenic factor-1 (SF-1)
5
.  DAX-1 has a slightly shorter splice 
variant, DAX-1A, which is spliced replacing exon 2 with exon 2A
5
.  DAX-1A is expressed at a 
lower level and its significance remains unknown
5
.     
DAX-1 function is well accepted as a negative coregulator of other nuclear receptors including  
SF-1, a key transcriptional regulator of steroidogenic and reproductive tissues
18
.  Missense 
mutations in the DAX-1 gene of AHC patients affect DAX-1’s ability to translocate to the 
nucleus and its ability to bind corepressors to form an active corepressor complex
18
.  In DSS, 
increased expression of DAX-1 is thought to antagonize SRY (TDF, testis determining factor) 
leading to development of female reproductive tissues and structures
19
.  In 2000, Zhang et al. 
observed DAX-1 binding to ligand-activated estrogen receptor alpha (ERα) and estrogen 
receptor beta (ERβ) via the leucine rich motif, repressing ER activity by preventing its ability to 
bind DNA
20
.  In 2008, Sablin et al. solved the crystal structure of the DAX-1 LBD 
homodimerized and bound to LRH-1 via a repressor helix motif, PCFXXLP
21
.  Some evidence 
shows DAX-1 may act at the gene level as part of a larger repressor complex.  In 2010, Lanzino 
et al. found that after stimulation with dihydrotestosterone (DHT), an androgen hormone, DAX-
1 and HDAC-1, as part of an AR-mediated repressor complex were able to reduce the levels of 
cyclin D1 in MCF7 breast cancer cells
22
.   In summary, DAX-1 repressive function in normal 
individuals is achieved through activity of both the LXXLL motif and LBD, and is necessary for 
normal development and maintenance of steroidogenic tissues.  
DAX-1 has been implicated in cancer, most notably in Ewings sarcoma where it is highly 
expressed and may be required for oncogenesis
23
.  Intriguingly, DAX-1 may also have a tumor 
suppressive role in certain cancer types.  Introduction of DAX-1 into MCF7 breast cancer cells 
reduces cell proliferation in vitro and reduces tumor size in a mouse xenograft model 
19 
 
(Tzagarakis-Foster, unpublished).  Overexpression of small heterodimeric partner (SHP/ 
NR0B2), an orphan nuclear receptor closely related to DAX-1, in hepatocellular carcinoma 
inhibited tumor growth and increased sensitivity to apoptosis
24
. 
 Epigenetic regulation of Nuclear Hormone Receptors 
In mammals and other higher eukaryotes, genes can be regulated by epigenetic mechanisms 
including DNA methylation at cytosine bases and histone post-translational modifications 
(further discussed in chapter 3,4).  Epigenetic changes are heritable from cell to cell and from 
organism to organism.  Epigenetic regulation of nuclear receptors may partially explain their 
precisely regulated schedule of expression and absence during development
34
.  Aberrant changes 
in DNA methylation at NR promoters may disrupt the balance of the NR gene-regulation 
network, leading to dramatic physiological effects
25
.  Increased methylation of promoter DNA is 
thought to repress gene expression by several mechanisms including steric blockage of 
transcriptional activators, and recruitment of methyl-DNA binding proteins that can remodel 
chromatin to a tightly bound, inactive state
26
 (Fig. 1-6).   
Clinical Relevance of Nuclear Receptors 
Scientists in industry and academia have long targeted nuclear receptors in efforts to treat many 
diseases.  The basic paradigm of nuclear receptor activity being modulated by the presence or 
absence of ligand has spurred the search for and synthesis of many synthetic activators and 
deactivators of nuclear receptors
27
. Knowledge of the receptors, their structure and mechanisms 
of action, recruited cofactors, and targeted genes allow for rational drug design
28
.  Two examples 
of blockbuster synthetic drugs targeted at nuclear receptors include Tamoxifen for estrogen-
mediated breast cancer and Dexamethazone, a glucocorticoid agonist that has anti-inflammatory 
activity.  Knowledge of the expression and epigenetic status of DAX-1 may one day provide  
20 
 
 
Figure 1-6.   Simplified schematic of cytosine methylation cycle in higher eukaryotes.  Filled 
circles represent methylated CpG sites and empty circles represent unmethylated CpG sites.  
Left, unmethylated DNA in the 5’ regulatory region of a gene allows an open chromatin state and 
active transcription.  Middle, CpG sites are methylated by DNA methyltransferases (DNMTs) 
and recognized by methylated DNA binding proteins such as MeCP2.  Right, CpG are oxidized 
by ten-eleven translocation (TET) family proteins and return to unmodified status.   
information necessary to develop treatments for DAX-1 associated diseases, AHC and DSS, as 
well as certain types of cancer.  
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well as certain types of cancer.  
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CHAPTER 2: DETERMINATION OF DAX-1 EXPRESSION 
INTRODUCTION 
DAX-1 expression 
 DAX-1 has a restricted expression pattern mainly present in the 
Hypothalamic/Pituitary/Gonadal axis (HPA-axis), as well as other tissues involved in steroid 
hormone production and reproduction such as Leydig and Sertoli cells in the testis and granulosa 
cells in the ovary
18
(Fig. 2-1).  DAX-1 expression co-localizes with steroidogenic factor-1 (SF-1), 
a transcriptional activator involved in sex determination and adrenal development.  DAX-1 acts 
as an anti-steroidogenic factor by repressing the actions of SF-1 and liver receptor homolog-1 
(LRH-1) and decreasing the levels of steroidogenic pathway genes such as aromatase
29
.  
Duplication of the region of the X chromosome containing DAX-1, and thus higher DAX-1 
expression, leads to a syndrome in which an XY individual develops as female
16
.  In contrast, 
loss of DAX-1 protein function due to inactivating mutations causes improper adrenal 
development and adrenal hormone insufficiency
15
.   
DAX-1 expression in stem cells 
Dax-1 is highly expressed in mouse embryonic stem cells
30
.   Dax-1 expression is required to 
maintain pluripotency in mouse embryonic stem cells and the loss of Dax-1 in stem cells by 
knockdown or gene inactivation results in differentiation
30,31
.   Although introduction of Dax- 
23 
 
 
Figure 2-1.  DAX-1 relative mRNA levels in many tissue types.  Notable DAX-1 expression is 
detected in the testis, ovaries, adrenal gland, and pituitary gland.   Figure obtained from the 
Nuclear Receptor Signaling Atlas (www.nursa.org).   
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1 into differentiated cells is not sufficient to induce pluripotency, Dax-1 has been observed 
bound to promoters of essential pluripotency factors such as Oct3/4, suggesting Dax-1 has a 
major role in repression of differentiation-regulated genes
31
.  
DAX-1 expression in cancer 
DAX-1 expression is also altered in cancer cells. The levels of DAX-1 in adrenocortical 
neoplasms are inversely related to the steroidogenic activity, suggesting that DAX-1 inhibits 
steroidogenesis
32
.   Another observation of DAX-1 by immunoreactivity was directly correlated 
to androgen receptor (AR) status in breast cancer
33
. This finding suggests that DAX-1 has the 
ability to bind and sequester AR in the cytoplasm, changing the activity of an important nuclear 
receptor in breast cancer diagnosis and treatment. Transfection of DAX-1 into cells of the well 
classified MCF7 breast cancer cell line  reduces proliferation in vitro and tumor size in a mouse 
xenograft model (Tzagarakis-Foster, unpublished).  Additionally, patients whose breast tumors 
express DAX-1 have a more favorable prognosis
34
.  Loss of ER regulation in breast cancer cells 
by DAX-1 may lead to upregulation of ER target genes such as cyclin D, which controls the 
G1/S transition of the cell cycle and subsequent replication of the cell
22
.   
DAX-1 may also contribute to lung cancer tumorigenicity by maintaining cancer stem cells
35
. 
DAX-1 is highly expressed in the human lung adenocarcinoma cell line A549
36
, making it a 
routinely utilized cell line for DAX-1 research. 
Investigation into DAX-1 expression 
To determine levels of DAX-1 expression in different human cell lines and justify a model 
system for studying the regulation of DAX-1 expression, relative abundance of DAX-1 mRNA 
levels was measured across the MCF7/MCF10F human breast cancer tumor/normal pair, as well 
as the A549 cell line. Although some is known about DAX-1 expression in these cell lines, never 
25 
 
has DAX-1 expression been directly measured between MCF7/MCF10F and A549 cell lines in a 
focused single gene study.  DAX-1 expression data will lay the groundwork for further studies 
into the epigenetic regulation of DAX-1 in these cell lines.   
MATERIALS AND METHODS 
Cell culture 
MCF7, MCF10F, and A549 cells were obtained from the American Type Culture Collection  
(ATCC).  MCF7 cells are known to express estrogen receptor and are responsive to estrogen, so 
were grown in media lacking phenol red because of its potential endocrine disruptive actions.  
Base DMEM/F-12 media was supplemented with 10% FBS and other growth factors as 
described by ATCC.  Cells were grown in T25 and T75 cell culture flasks with vented caps, and 
passaged 2-4 times per week, as described by ATCC recommended culture and subculture 
protocols.  Cells in T25 flasks were grown with 3 ml media, and cells in T75 flasks grown with 
12-15 ml media.  Average cell number counted from a near confluent T75 flask was between 3-6 
million cells, depending on cell line and growth characteristics.  Cell lineages were discarded 
after 20 passages.     
RNA isolation 
MCF7, MCF10F, and A549 cells were grown to 50-70% confluency after 24hrs in  6-well plates.  
Cells were lysed directly on the plate with buffer RLT from the QIAGEN RNeasy RNA isolation 
kit (Valencia, CA).  RNA was isolated with QIAGEN spin column technology following the 
standard protocol including optional RNAse-free DNA digestion to remove genomic DNA 
contaminants.  RNA was immediately used as template for cDNA synthesis, or stored at -80°C 
for a maximum of 24 hours.   
26 
 
cDNA synthesis 
cDNA synthesis was performed with standard protocol using the Applied Biosystems high 
capacity cDNA reverse transcription kit (Thermo Fisher Scientific, Waltham, MA). cDNA was 
synthesized using random primers and a three step incubation:  25 °C for 10 min, 37 °C for 120 
min, 85 °C for 5 min.  cDNA yield produced from one well of 50-70% confluent cells in a  6-
well plate was on average,  >1000ng/µl.     
Endpoint-PCR and visualization 
Endpoint-PCR was performed with Promega GoTaq2x green master mix.  Endpoint-PCR was 
performed with a thermal cycler using the following conditions: 95°C denaturation step for 3 
min (1 time), 95°C for 30s -> 58°C for 30s -> 72°C for 10s (32 times), 72°C for 4 min (1 time). 
Primers used to assay DAX-1 expression were: forward:  5’ – 
ATCAGTACCAAGGAGTACGCC – 3’, reverse: 5’ – GTTCCCCACTGGAGTCCCTG – 3’, at 
an annealing temperature of 58°C. Primers used to assay GAPDH expression were: foward: 5' - 
TTGCCATCAATGACCCCTTCA - 3, reverse: 5' - CGCCCCACTTGATTTTGGA - 3', at an 
annealing temperature of 58°C.  Endpoint-PCR products were separated by electrophoresis 
through a 2% agarose gel with ethidium bromide added, and visualized by ultraviolet radiation.  
Quantitative reverse transcriptase PCR 
qPCR was performed with the BioRad (Hercules, CA) CFX-96 system using iQ SYBR-Green 
supermix.  High amounts of cDNA per sample (1-2μg) were used to ensure reproducible 
amplification of DAX-1, a low abundance transcript in MCF10F and MCF7 cell lines.  Primers 
were designed to span the Exon1-Exon2 junction, with a 125 bp amplicon.  Fold difference in 
expression was calculated using the delta Ct method: 
2^(Cq(sample) – Cq(standard)) 
27 
 
For relative gene expression comparisons, GAPDH was used as a standard reference gene.  
GAPDH expression was uniform across all samples, and melting curves were checked to ensure 
the absence of primer-dimer. PCR conditions and primers used were the same as used in 
endpoint-PCR (see above). 
P-values were calculated using a paired, one-tailed student's t-test to compare the relative 
expression across the three cell lines.   Error bars were created using the standard deviation of the 
relative expression across the three cell lines. Results are representative of three replicates of 
qPCR gene expression analyses using input cDNA synthesized from mRNA collected from 
separate cell populations.         
RESULTS  
Creation and validation of a model system of two tumorigenic environments with opposite-
spectrum levels of DAX-1 expression is required for study of the epigenetics of DAX-1, the 
focus of later chapters and main goal of this research.  Although an overview of DAX-1 
expression data in normal adult tissues is available in the literature (Fig. 2-1), a direct single-
gene comparison of DAX-1 expression between the two cell lines MCF7 and A549, including 
MCF10F cells as a normal tissue control, is first reported here.  By endpoint-PCR visualization 
with gel-electrophoresis, amplification of an exon-spanning region of DAX-1 revealed very low 
expression of DAX-1 in MCF7 cells, and a slightly brighter band given by MCF10F cells (Fig. 
2-2).  DAX-1 expression was observed to be very high in A549 cells compared to both MCF7 
and MCF10F cells by standard gel electrophoresis.  Relative quantitative analysis by qPCR 
demonstrated DAX-1 expression in MCF10F was 4.6 times higher than in MCF7 (Fig. 2-3).  
DAX-1 expression in A549 was 406 times higher than in MCF7 (Fig. 2-4). DAX-1 expression in 
A549 cells was 86.4 times higher than in MCF10F cells(Fig. 2-5).   
28 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2 DAX-1 reverse transcriptase-PCR visualized by 2% agarose gel electrophoresis.  
MCF7 cells have very low DAX-1 expression. MCF10F cells have slightly greater DAX-1 
expression than MCF7 cells.  A549 cells show relatively high DAX-1 expression.  Vertical line 
denotes spliced image from different samples within the same experiment.   
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Figure 2-3.  Results from qPCR  analysis of DAX-1 cDNA.  MCF10F cells express  4.6 times 
the level of DAX-1 compared to MCF7 cells.  The MCF7/MCF10F cell line comparison 
represents a cancer/normal model system for ER+ breast cancer. 
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Figure 2-4. Results from qPCR  analysis of DAX-1 cDNA from MCF7 cells compared to A549 
cells.   A549 cells express DAX-1 406.5 times more than MCF7 cells.     
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Figure 2-5.  Results from qPCR  analysis of DAX-1 cDNA from MCF10F cells compared to 
A549 cells. A549 cells express DAX-1 86.4 times more than MCF7 cells.     
 
 
 
 
 
 
 
 
 
32 
 
DISCUSSION 
These results demonstrate a reliable system to study the epigenetic regulation of DAX-1, the goal 
of research conducted in later chapters of this report.  The MCF7/MCF10F comparison 
represents a medically relevant disease model where a low DAX-1 expressor in a cancer 
environment (MCF7) can be compared to a physiological DAX-1 expressor in a normal 
environment (MCF10F).  DAX-1 as a nuclear receptor repressor is especially important in breast 
tissue due to its ability to repress the activity of activated estrogen receptor (ER), a biomarker of 
the majority of breast cancers.  Although beyond the direct scope of this research, the loss of ER 
repression due to diminished levels of DAX-1 is a valuable hypothesis that may be further 
studied.  These studies demonstrate the A549 cell line expresses DAX-1 at a level much higher 
than MCF7 or MCF10F. I was also able to validate that this finding agrees with relative 
expression levels found in the Cancer Cell Line Encyclopedia (Fig 2-6).  A549 represents a 
valuable research tool where the effects of DAX-1 function, and the repercussions of loss of 
DAX-1 by genetic manipulations, may be easily studied.  Here, the inclusion of the A549 cell 
line represents a predicted control for methylation studies, in that we expect no epigenetic 
repression of DAX-1 in this cell line.  DAX-1 is expressed at a level much higher than MCF7, 
and if the DAX-1 gene is regulated by methylation, one would expect the methylation levels of 
DAX-1 DNA to be very different in these cell lines.  Following the cancer methylation 
paradigm, DAX-1 DNA in A549 may be strongly unmethylated compared to MCF7.   Although 
the effect of greatly increased DAX-1 in A549 lung cancer cells is unclear, one possibility is that 
epigenetic mechanisms contribute to its profound overexpression and the tumorigenicity of this 
cell line.     
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Fig 2-6.  A549 cells show higher DAX-1 expression than in MCF7 breast cancer cell lines, 
validating the PCR and qPCR data presented above. Figure created with data from the Caner Cell 
Line Encyclopedia (CCLE), http://www.broadinstitute.org/ccle/home 
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CONCLUSION 
DAX-1 expression was first investigated by querying several sources within the vast literature of 
cancer transcriptomics and nuclear receptor specific expression data.  DAX-1 is highly expressed 
in reproductive tissues such as the testis and ovaries, other endocrine tissues such as the adrenal 
gland, and in the cancer cell line A549.  DAX-1 expression in the MCF7/MCF10F human cell 
line breast cancer model is significantly lower than in A549 cells.  However, the low but still 
detectable DAX-1 expression levels in MCF10F cells represent a physiologically normal level in 
this tissue.  Lower, barely detectable expression of DAX-1 in MCF7 cells may be associated 
with the breast cancer disease state. In summary, two cancer cell lines were assayed for DAX-1 
expression and found to have significantly different expression compared to a normal breast 
tissue cell line, laying a foundation for further studies of DAX-1 epigenetic gene regulation.    
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CHAPTER 3:  DETERMINATION OF DAX-1 METHYLATION STATUS 
INTRODUCTION 
Epigenetics and DNA methylation 
Epigenetics can be defined as a heritable change in cellular phenotype that is caused by 
mechanisms independent of a change in the DNA sequence.  Although the term epigenetics may 
encompass many cellular processes, it is usually used to refer to DNA methylation, a well 
classified epigenetic modification that can have drastic changes on the cellular phenotype.  DNA 
methylation, first observed  in humans in 1948
37
, is now considered by many to be the fifth base 
of the human genome.   DNA methylation occurs in humans on the 5’ carbon of the cytosine ring 
(Fig 3-1) primarily when cytosine is paired with guanosine, as a part of a ‘CpG’ dinucleotide38.  
Lower eukaryotes and bacteria use different epigenetic schemes including modifications of 
several bases
26
.   5-methylcytosine (5mC) is not uniformly spread throughout the genome
26
.  The 
CpG dinucleotide is present in a much lower frequency than predicted, except for in CG rich 
regions denoted ‘CpG islands’, often present in the 5’ regulatory regions of genes38.  5-mC 
presence in CpG islands is often associated with transcriptional repression
39,40
, and high levels of 
CpG methylation is responsible for transcriptional silencing of tumor suppressor genes in many 
types of cancer
41
.  Non CpG methylation, discovered more recently, is found in some human 
tissues
42
.  Well documented in the nervous system, non-CpG methylation may suggest a broader 
role of gene regulation by DNA methylation occuring outside of CpG islands
42
.   In the world of 
epigenetics, there exist ‘readers, ‘writers’, and ‘erasers’ 43.  Writers such as the DNA 
methyltransferases are able to methylate DNA both de novo and from hemi-methylated substrate 
after cell division
44
.   
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Figure 3-1. Cytosine methylation scheme.  A methyl group is added the to the 5' position of 
cytosine in the DNA of higher eukaryotes by DNA methyl transferase enzymes (DNMT's). 
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Readers such as MeCP2 are able to selectively bind methylated DNA and recruit other factors 
that affect cell phenotype through chromatin remodeling
44
.  Erasers such as the Ten-eleven 
translocation (TET) family of enzymes oxidize 5mC,which is the first step in removal of the 
methyl group
45
. 
Scope of Epigenetic Modifications 
It has recently become apparent that the “epigenome” or the set of all epigenetic modifications to 
the genome plays a large role in cellular and organismal phenotype.  Studies have shown 
epigenetic links to common diseases such as obesity
46
 and cancer
47
.  Epigenetic modifications 
are sensitive to the environment and behavior of an individual
48
.  Behaviors such as smoking 
tobacco
49
 affect modifications to DNA and have the potential to be passed on to gametes. The 
methylation patterns of pluripotent cells are unique, including robust methylation of specific 
developmental regulator genes
50
.   Different types of pluripotent stem cells are defined by their 
epigenetic hallmarks
50
, including non-CG methylation and 5-hydroxymethylcytosine, a ‘sixth’ 
base pair whose function is not yet clear
40,45,51
.  A recent study with importance to regenerative 
medicine analyzed methylation patterns between several variations of induced pluripotent stem 
cells (iPS) to determine which method of generation produce an iPS product most similar to 
embryonicstem cells
52
.   The methylation patterns of stem cells, and potentially many types of 
cells, can be used to judge the differences between populations of the same types of cells.   
Methylation analysis 
Although many different technological methods exist for methylation analysis, bisulfite 
sequencing (Fig 3-2) is considered the 'gold standard' for methylation analysis and uses a 
chemical reaction to convert unmethylated cytosines to uracil, leading to a C->T change 
observed after sequencing.   
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Figure 3-2. Bisulfite sequencing scheme. Filled black ovals represent methyl groups.  Traditional 
sequencing of untreated DNA gives no information about methylation status (left).  After 
conversion of unmethylated cytosine to uracil with bisulfite, and performing PCR amplification 
and sequencing, unmethylated cytosine appear as a C -> T change compared to the original 
sequence (right). By observing C -> T after bisulfite sequencing and comparing to a reference 
sequence, the location of each methylated and unmethylated cytosine can be deduced. 
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Methylated cytosines remain unmodified and are observed as expected in a sequencing reaction.   
Recently, knowledge about the importance of epigenetics have come from epigenome wide 
association studies (EWAS), where novel high throughput methylation assays can be used to 
map associations to disease and physical traits
53
.   
A major next-generation methylation analysis tool uses methylated DNA hybridization to assay 
many CpG sites in the human genome; however, the tool only assays a mere 2 CpG sites within  
DAX-1, providing little meaningful data about the methylation status of the DAX-1 gene and 
promoter.  Much research is needed into the mechanism and functions of DNA methylation and 
other epigenetic modifications.    
DAX-1 methylation in human cells 
To study methylation levels of DAX-1, the well classified and commonly used cancer cell lines 
MCF7 and A549 were used. MCF7 represents a breast cancer environment where DAX-1 
expression is low, and A549 represents a lung cancer environment where DAX-1 expression is 
very high (see: Chapter 2, DAX-1 expression). The MCF10F normal breast cell line was used to 
represent a normal level of DAX-1expression in adult cells.  DAX-1 genomic DNA was 
analyzed for regions that satisfy the definition of a CpG island.  To examine the methylation 
levels of DAX-1, a simple qualitative assay was first employed with a methylation sensitive 
restriction digest. To further study the methylation levels of DAX-1 at regions of interest within 
the CpG island, bisulfite sequencing was performed with three cell lines, mentioned above, 
known to express DAX-1 differentially.  The aim of work in this chapter is to analyze 
methylation status in human cells and observe the relationship between methylation status and 
gene expression. Additionally, observation of methylation may allow identification of specific 
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differentially methylated regions within the CpG island that may be where mechanistic pathways 
of transcriptional regulation are focused.      
MATERIALS AND METHODS 
Prediction of DAX-1 CpG Island 
DAX-1 genomic DNA sequences (ID:190) from Homo sapiens and Mus musculus were obtained 
from the National Center for Biotechnology Information’s (NCBI) GenBank database  
Calculation and visualization of a CG rich region in the promoter region of the DAX-1 genomic 
DNA sequences in human and mouse was accomplished with MethPrimer
54 
software, using 
default prediction parameters.  CpG islands were defined as a DNA segment with a minimum 
length of 100bp, >50% CG content, and an observed-to-expected CpG ratio greater than 60%. 
Observed-to-expected CpG ratio is calculated where: 
observed = (number of CpGs/length of sequence), 
expected = (((number of C + number of G) / length of sequence) / 2)
2
. 
Sequence alignment 
DAX-1 human and mouse coding sequence DNA were obtained from the NCBI Nucleotide 
database and aligned with the Clustal Omega multiple sequence alignment program using default 
parameters. Genomic sequence was not aligned between mouse and human due to low homology 
between non-coding sequences, including the DAX-1 intron and region upstream of 
transcriptional start site.  Clustal Omega is a freely available tool found at 
http://www.ebi.ac.uk/Tools/msa/clustalo/   
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Methylation Sensitive Restriction Digest (MSRD) 
MCF7, MCF10F, and A549 cells were grown to 70-90% confluency (see: cell culture methods, 
Chapter 2) and genomic DNA was extracted with the Sigma-Aldrich (St. Louis, MO) 
mammalian genomic DNA miniprep kit.  Genomic DNA from each cell line was digested with 
HpaII for 12-16 hours at 37°C.  Digested DNA was used as a template for endpoint-PCR and 
methylation trends were qualitatively analyzed by gel electrophoresis using 2% agarose gels with 
ethidium bromide.  Photographs of agarose gel DNA visualizations were selected as 
representatives of the average of three independent experiments.  Primer sequences are below: 
 Forward Reverse 
MSRD Fragment 1 CCCTCCCAATAAAGGGAAC
A 
GCTGGAAATGGAAGA
ACAGC 
MSRD Fragment 2 CCGTGGCACTCCTGTACC GGTAGCGCCTCTTTAC
CCC 
MSRD Fragment 3 CTGTTCGTGCGGCTCTGAT ACCAGAGGAGGTGTC
CCAC 
GAPDH TTGCCATCAATGACCCCTTC
A 
CGCCCCACTTGATTTT
GGA 
 
Endpoint-PCR 
Endpoint-PCR was performed with Promega GoTaq2x green master mix.  Endpoint-PCR was 
performed on a thermal cycler with the following conditions: 95°C denaturation step for 3 min (1 
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time), 95°C for 30s -> 58°C for 30s -> 72°C for 15s (30 times), 72°C for 4 min (1 time). 
Endpoint-PCR products were separated by electrophoresis through a 2% agarose gel with 
ethidium bromide added and visualized by ultraviolet radiation.  
Bisulfite Sequencing Primer Selection 
Bisulfite specific primers were picked using guidelines discussed in Li L.C. et al.
54
: 1. to avoid 
biased amplification the primer sequence must not contain a CG dinucleotide, 2. the primer 
sequence must contain a minimum amount of non-CpG C's to decrease the chance of amplifying 
a non-bisulfite converted DNA fragment, 3. the primer sequence should be at least 25 
nucleotides long. Only a small number of regions in the DAX-1 CpG island satisfied these 
requirements, and several potential bisulfite sequencing primers were tested with an annealing 
temperature gradient PCR amplification program before three validated primer sets (bisulfite 
fragments 1-3: see below) were chosen for further use. Annealing temperature gradient PCR 
involved standard endpoint-PCR conditions described above, however a gradient of 48-60°C was 
applied across 8 separate duplicate samples during the annealing phase. After gel electrophoresis 
and visualization, primers that produced a single, bright band were selected and others discarded. 
Bisulfite Conversion and Cloning Bisulfite Amplicons 
Genomic DNA was  isolated from three seperate cell populations using the Sigma-Aldrich 
mammalian genomic DNA minprep kit.  Genomic DNA (1μg) was treated with bisulfite using 
the Life Technologies (Carlsbad, CA) Cells-to-CpG bisulfite conversion kit according to the 
manufacturer’s protocol.  Bisulfite converted gDNA was amplified with bisulfite specific 
primers (sequences shown below) over two consecutive PCR reactions, using the product of the 
first reaction as template for the second reaction.  The product of the second PCR reaction was 
electrophoresed on 2% agarose gel, and extracted and purified with the QIAGEN Qiaquick gel 
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extraction kit according to the manufacturer’s protocol.  3μL of the purified PCR product was 
ligated into the Promega (Madison, WI) pGEM T-easy vector system with the supplied T4 DNA 
ligase overnight at 4°C, following the manufacturer’s protocol.  The ligation product was used to 
transform Promega JM109 competent E. coli cells.  Transformed E. coli were grown on LB-Amp 
plates for 12-16 hours at 37°.  Potentially transformed colonies were selected based on size and 
isolation and were subject to colony PCR with bisulfite specific primers to confirm presence of 
the insert of interest.  Colonies containing the insert of interest, as confirmed by colony PCR, 
were picked and grown overnight under ampicillin selection.  Cultures were grown at  37°C for 
12-16 hours in a shaker incubator and plasmid DNA was isolated from cells with the Zymo 
Research Corporation (Irvine, CA) Zyppy plasmid miniprep kit.  Concentration and purity of 
plasmid DNA was measured by a GE Healthcare Nanovue spectrophotometer.  Samples with a 
concentration >60μg/μL and 260/280nm absorption ratio near 1.8 were used as a template for 
direct sequencing by Molecular Cloning Laboratories (South San Francisco, CA).  
 
 Forward  Reverse 
Bisulfite Fragment 1 GTTGTTGTTTTTTTATTTTT
AGTTTTTAAAGA 
AACCCAATTCTACCCAATAA
CTACCTTTTAAA 
Bisulfite Fragment 2 GTAGTTATTGGGTAGAATT
GGGTTA 
AACAACATCCTCTACAACAT
ACTAAC 
Bisulfite Fragment 3 AGTGGTAGGGTAGTATTTT
TTATAATATGT 
AATAATCTTCACCACAAAA
ACAACA 
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Colony PCR 
To confirm the ligation of an insert of interest into the pGEM vector system, transformed E. coli 
cells were picked off of selective media (LBamp) plates and were directly used for PCR 
amplification.  All PCR were conducted using Promega GoTaq2x green master mix.  A longer 
initial denaturing step (3:30 at 95°C) was used to ensure lysis of cells and denaturing of DNA.  
After PCR, reactions were gel electrophoresed and the presence of a strong band of the 
appropriate size was confirmed before colonies were used for overnight cultures and plasmid 
DNA isolation 
Bisulfite Converted DNA Sequence analysis 
Bisulfite converted DNA sequence files (ABI format) were imported into Sequencher software 
(Gene Codes Inc).  Sequence files were aligned to a DAX-1 methylated reference sequence 
which was bisulfite converted in silica.  Bisulfite specific primers were aligned to the reference 
sequence to confirm the beginning and ending of each amplicon of interest.  Each CpG site of 
each clone was observed for a C -> T change, indicating an unmethylated cytosine on the 
originally extracted genomic DNA from cultured mammalian cells.  An unchanged C in a CpG 
site indicated a methylated cytosine.  A minimum of 8-10 clones were sequenced for each 
amplicon of interest for each cell line, with DNA samples extracted from 3 separate populations 
of cells.  A value of 1 was given to a methylated CpG site, and a value of 0 to an unmethylated 
CpG site.  The percent methylation at each CpG site was calculated by dividing the number of 
methylated clones by the total number of clones sequenced.  P-values were calculated using a 
paired, one-tailed student's t-test to determine if the differences in methylation were significant. 
The set of percent methylation values for each fragment for each cell line was compared across 
the other cell lines tested. 
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RESULTS 
CpG Island Identification 
The 5' region of DAX-1 upstream of the transcriptional start site and into the first exon were 
found to contain a CG rich region containing many CpG sites, with total CG content between 
~60-80% (Fig. 3-3).  Downstream of the first 1500bp of the DAX-1 gene, the CG content drops 
sharply to the ~20-50% range, and only a few CpG sites are found for the next ~3500bp through 
a large intron to the end of exon 2 and the genic region.   
To determine if this CG content and CpG pattern was conserved across species or just a 
phenomenon in humans, the DAX-1 coding sequence was first aligned with coding sequence 
from Mus musculus (Fig. 3-4).  The DAX-1 coding region in human and mouse have 73%  
sequence similarity.  Next, the CpG islands of the coding regions were identified and compared 
(Fig. 3-5).  Both mouse and human DAX-1 coding region sequences contain CpG rich regions of 
similar position and CpG density. However, the mouse CpG islands are slightly smaller and less 
CpG rich than those in human.  The mouse NR0B1 coding region contains 76 CpG sites 
distributed between four separate CpG islands. The human NR0B1 coding region contains 105 
CpG sites distributed between four separate CpG islands, each larger and containing more CpG 
sites than their corresponding similarly positioned CpG island in the mouse coding region.   
Methylation Sensitive Restriction Digest 
To qualitatively observe methylation patterns of DAX-1 across MCF7, MCF10F, and A549 cell 
lines, genomic DNA was digested with HpaII and used as template for endpoint PCR (Fig. 3-6).  
In all cases, A549 template was not protected from HpaII digestion and produced a barely 
detectable PCR product, suggesting non-methylated DNA across many loci.  MCF7 and  
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Fig 3-3. CG content and CpG site analysis of human DAX-1 genomic DNA. CpG islands are 
highlighted in blue.  The DAX-1 promoter and exon 1 region show high CG content and contain 
many CpG sites. The intron region is observed as a  CpG desert, where CG content is low and 
few CpG sites are observed.   
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Figure 3- 4. Alignment of DAX-1 coding sequences.  Homo sapiens: top, Mus musculus: bottom. 
Blue indicates identity (73%), red indicates mismatch. 
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Figure 3-5. CpG island analysis of mouse and human DAX-1 coding sequences. CpG island 
regions are highlighted by blue columns. Mouse and human coding sequences show four distinct 
CpG island regions each. The human coding region contains more CpG sites than the mouse 
coding region (total human CpG:105, total mouse CpG:76), and there are many areas of 
overlapping CpG richness.  
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Figure 3-6. Methylation sensitive restriction digest of genomic DNA showing digested (D) and 
undigested (U) samples. The presence of a band in the digested sample indicates high 
methylation levels. The lack of a band in the digested samples indicates low methylation levels. 
A549 cells show low DAX-1 methylation in all three observed fragments. Vertical lines denote 
spliced image.     
 
 
 
 
 
 
 
50 
 
MCF10F templates were much more protected from digestion and produced PCR products 
similar in intensity to the undigested samples, suggesting that this DNA is methylated.  MCF10F 
template in the fragment 3 region shows a slightly less intense band in the digested sample 
suggesting the restriction sites may have been partially unmethylated.   
Bisulfite Sequencing 
An ~700bp region of the DAX-1 CpG island was divided into 3 sections referred to as fragment 
1-3, and are labeled in order of most 5' to most 3'. The fragments represent large sections of the 
DAX-1 CpG island where bisulfite specific primers could be properly designed and validated for 
use (Fig. 3-7).  For bisulfite sequencing analysis, P-values shown compare methylation of each 
cell line against MCF10F. Differential methylation between the MCF7, MCF10F, and A549 cell 
line was observed in fragment 1 (Fig. 3-8). MCF7 shows high methylation typically between 80-
100%, whereas MCF10F methylation is lower at most CpG sites. Fragment 2 of the CpG island 
shows the greatest differential methylation between MCF7 and MCF10F, and A549 is entirely 
unmethylated (Fig. 3-9). Fragment 3 is the longest and most 3' region observed within the DAX-
1 CpG island, and shows differential methylation of MCF7 and MCF10F between CpG sites 1-
19 (Fig. 3-10).  CpG sites 20-38 of fragment 3 are not differentially methylated in MCF7 and 
MCF10F cells (p > .05); however, most CpG sites of fragment 3 are entirely unmethylated in 
A549 cells.  
DISCUSSION 
The methylome, or methylation status of the genome, is important in regulation of gene 
expression in development, healthy adulthood, and many disease states including cancer. In the 
cancer cell lines studied here, there exists an inverse relationship between DAX-1 expression and 
methylation.  Further study into the cause and effects of differential regulation of DAX-1 is  
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Figure 3-7. Locations of three bisulfite sequencing fragments in the DAX-1 CpG island. 
Fragment 1 contains 21 CpG sites, fragment 2 - 19 CpG sites, and fragment 3 - 38 CpG sites. 
The bisulfite sequencing fragments are named in order of most 5' to most 3'.   
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MCF7  p = 3.8 x 10
-5 
A549  p = 2.68 x 10
-12 
 
Figure 3-8. Bisulfite fragment 1. MCF7, MCF10F, and A549 DNA are differentially methylated 
at the DAX-1 CpG island.  MCF7 shows highest methylation percentages across most CpG, and 
A549 is umethylated at all but one CpG site.  P-values were calculated using a student's t-test to 
determine the significance of differential methylation between MCF7/A549 and MCF10F cells.  
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MCF7 p = 1.59 x 10
-10 
A549 p = 8.24 x 10
-11 
 
Fig 3-9. Bisulfite fragment 2. MCF7, MCF10F, and A549 DNA are differentially methylated at 
the DAX-1 CpG island.  MCF7 shows highest methylation percentages across most CpG, and 
A549 is  entirely unmethylated.  Fragment 2 of the DAX-1 CpG island shows the greatest 
differential methylation between MCF7, A549, and MCF10F cell lines. P-values were calculated 
using a student's t-test to determine the significance of differential methylation between 
MCF7/A549 and MCF10F cells.   
 
 
 
 
 
 
54 
 
MCF7 p = 1.82 x 1';';0
-7
* 
A549 p = 4.5 x 10
-7
* 
 
Figure 3-10. Bisulfite fragment 3.  MCF7, MCF10F, and A549 DNA are differentially 
methylated at the DAX-1 CpG island. Beyond CpG 19 in the 3' direction, methylation levels of 
MCF7 and MCF10F converge. The DAX-1 CpG islandin the A549 cell line  shows very low 
levels of methylation throughout fragment 3. P- values were calculated using a student's t-test to 
determine the significance of differential methylation between MCF7/A549 and MCF10F cells. * 
P-values shown above only include CpG sites 1-19. Methylation difference between MCF10F 
and MCF7 between CpG site 20-38 is non-significant. 
 
 
 
 
 
 
 
55 
 
needed, including epigenetic analysis of breast and lung cancer patients.  In the MCF7/MCF10F 
breast cancer model, we propose a mechanism to explain how loss of DAX-1 may contribute to  
the tumorigenic phenotype of these cells.  Estrogen receptor (ER) is a biomarker of the majority 
of breast cancer cases and accounts for the hormone sensitive, unregulated growth of breast 
cancers
6
.  DAX-1 is known to bind to and repress activity of ligand activated ER
20
, and perhaps 
loss of DAX-1 by excessive methylation allows ER activity to ascend to a dangerously high 
level.  This hypothesis could be tested in future studies by selectively demethylating DAX-1, and 
noting effects on MCF7 cell proliferation and tumor growth in a mouse xenograft model. 
In A549 cells, one hypothesis is that increased DAX-1 levels may be responsible for maintaining 
pluripotency of a small side population of cancer stem cells.  Additionally, knockdown of DAX-
1 in A549 reduces cell proliferation and invasion through matrigel
35
, suggesting that high levels 
of DAX-1 in A549 may result in repression of tumor supressor genes that are typically active 
under normal levels of DAX-1. 
The question remains: why is DAX-1 highly methylated in one cancer environment and 
unmethylated in another? Expression of epigenetically controlled genes is a function of the 
activity of the epigenetic readers, writers, and erasers that are expressed in a particular 
environment. To answer this question, one could begin by comparing the expression levels of 
many epigenetic factors with DAX-1 expression and methylation levels in many cell lines and 
cancer types. If a trend could be observed where a specific epigenetic factor was significantly 
associated with increased or decreased DAX-1 expression or methylation, this epigenetic factor 
could be the focus of additional focused investigation. Future experiments should include a 
knock down of epigenetic factors in cell lines where DAX-1 has abnormal expression, and 
observation of the following effects on DAX-1 expression and cell proliferation. 
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DAX-1 expression and methylation in mouse cells 
 The inverse relationship between DAX-1 expression and methylation found here has also been 
observed in mice when the CpG methylation status of DAX-1 in several Mus musculus cell lines 
was recently mapped (unpublished data, George Tzertzinis, New England Biolabs).  Of four cell 
lines assayed, DAX-1 expression was found in E14 and D3 cells (Fig. 3-11).  E14 and D3 cells 
are mouse embryonic stem cells, cell types where DAX-1 is highly expressed
30
.  Two somatic 
cell lines, NIH 3T3 and I10 did not show detectable DAX-1 expression.  Within the mouse 
DAX-1 CpG island, a groupof CpG sites labeled fragment 2 was identified to have the strongest 
differential methylation between the cell lines assayed (Fig. 3-12). Although the mouse CpG 
island contains fewer CpG sites, the trend of an inverse relationship between DAX-1 expression 
and methylation is conserved between many human and mouse cell lines. 
Clinical relevance of DAX-1 epigenetics 
 Epigenetic aberrations in disease provide a new avenue of medical treatment.  DNA methylation 
modifiers are an interesting route to treat disease caused by abnormal methylation patterns, and 
one methylation inhibitor, 5-azacytidine, is already on the market used to treat myelodysplastic 
syndrome.  However, 5-azacytidine is a global methylase inhibitor and follows the paradigm of 
non-targeting chemotherapy with unwanted side effects, demethylating the entire genome, with 
the potential to strongly affect gene expression.  It may soon be possible to edit the epigenome, 
altering the methylation state of single genes to a level considered physiologically normal for a 
specific tissue in the body.       
CONCLUSION  
A region of the DAX-1 gene has been identified as a CpG island, containing high CG content 
and a high ratio of CG dinucleotides.  The region, contained in the promoter and  5’ region of  
57 
 
 
 
Figure 3-11.  DAX-1 expression in mouse somatic and stem cell lines, relative to standard 
GAPDH. DAX-1 expression is detectable in E14 and D3 mouse embryonic stem cell lines. From 
Tzertzinis lab, at New England Biolabs, Inc   
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Figure 3-12.  DAX-1 methylation status in 4 mouse cell lines, as observed by bisulfite PCR and 
direct sequencing. Colored ovals represent CpG sites.  Methylation status was determined by 
analyzing sequence chromatogram CpG peaks for presence of C only (methylated), C and T peak 
(mixed), or T only peak (unmethylated).  Genomic region ‘Fragment 2’ shows mixed or 
unmethylated CpG in mouse embryonic stem cell lines compared to methylated or mixed in 
somatic cell lines. From Tzertzinis lab, at New England Biolabs, Inc. 
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exon 1 of DAX-1, contains CG methylation sites that are differentially methylated between a 
breast cancer and normal breast tissue cell line model system, and are completely unmethylated 
in the A549 lung cancer cell line.  The methylation pattern observed shows an inverse 
relationship with DAX-1 expression and provides a specific region to focus further investigations 
into DAX-1 methylation and the mechanism of regulation of DAX-1 by epigenetic factors. 
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CHAPTER 4:  DAX-1 INTERACTION WITH EPIGENETIC FACTORS 
INTRODUCTION 
Epigenetic modifications regulate gene expression 
A simplified model of eukaryotic chromatin describes DNA wrapped around several histone 
proteins akin to beads on a string
43 
.  Upon closer look, both the DNA and histone proteins are 
chemically modified in many ways, known as epigenetic modifications
43 
(Fig. 4-1).  These many 
different modifications have been identified as being associated with either transcriptional 
activation or repression of a gene at a given time. Epigenetic modifications are reversible, and 
can change over the lifetime of an individual organism, tissue, or cell.  The most common 
epigenetic modifications are DNA methylation on cytosine residues.  To affect gene expression, 
an epigenetic mark may passively change the physical architecture of the chromatin
26
,  and/or 
attract epigenetic 'readers' that actively recruit chromatin remodeling complexes and 
transcriptional cofactors.  Acetylation of histone proteins is generally thought to prevent DNA 
from wrapping tightly around the core histones, leading to an accessible chromatin 
environment
56
.  Methylation of histone proteins have been shown to have different effects on 
transcription depending on which residue of a specific histone protein is modified
43,56
.  
Modifications to DNA and chromatin are created, recognized, and reversed by DNA binding 
factors deemed the 'readers', 'writers', and 'erasers' of epigenetics. 
MeCP2 ('Reader') 
Methyl CpG binding protein 2 (MeCP2), a 50kDa protein encoded by the MECP2 gene on the 
X-chromosome
57
, is classified by its conserved methyl CpG binding domain (MBD) that allows 
the protein to specifically bind methylated DNA
44
.  MeCP2 has the ability to bind to a single  
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Fig 4-1.  Eukaryotic chromosomes are organized into DNA-wrapped nucleosomes (green 
cylinder) containing core histone proteins, akin to beads on a string. Chromatin also contains 
epigenetic modifications: DNA can be methylated at the 5' position of the cytosine ring (black 
ovals), and histone proteins may be acetylated or methylated (yellow ovals). Epigenetic 
modifications such as DNA methylation and histone acetylation are typically associated with 
repressed or active genes, respectively.   
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methylated CpG
 
site
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 and acts as a link between DNA methylation and transcriptional repression 
by recruiting chromatin remodeling factors such as histone deacetylases
44
  (Fig. 4-2). 
MeCP2 is known to be associated with Rett syndrome, an X-linked dominant 
neurodevelopmental disease that primarily affects girls
59,60
.  Mutations in MeCP2 are responsible 
for approximately 80% of Rett syndrome cases, but the exact mechanism by which a non-
functional MeCP2 leads to mental retardation is unknown
60
.  
MeCP2 is also implicated in cancer.  MeCP2 has been observed binding to hypermethylated 
tumor suppressor gene promoters in many cancer types
44
.
  
MeCP2 is also required for prostate 
cancer cell growth
61
 where silencing of tumor suppressor genes by DNA methylation through 
MeCP2 is a well-recognized process
62
. 
MBD1 ('Reader') 
Methyl CpG binding domain protein 1 (MBD1), a 55kDa protein, utilizes an MBD domain and 
multiple cysteine rich domains (CXXC)
63,64
 to bind methylated DNA.  MBD1 can recruit 
SETDB1, a histone methyl transferase (HMT) that creates a repressive chromatin environment 
through H3K9 methylation
65,66
.  
MBD1 is also found occupying the promoters of several epigenetically silenced tumor 
suppressor genes in cancer
44
. MBD1 is overexpressed in prostate cancer
67, 
and knockdown of 
MBD1 in prostate cancer derived cells dramatically reduces cell proliferation in vitro
68
. MBD1 
can recruit histone deacetylases to remodel chromatin
67
, but more research is needed to elucidate 
a canonical mechanism of gene silencing by MBD1.  
DNMT1 and DNMT3 ('Writers') 
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Fig 4-2. Three proposed mechanisms for modulation of gene expression by DNA methylation.  
1. Steric hindrance prevents transcription factors from binding. 2. Epigenetic readers such as 
MeCP2 bind to methylated DNA and recruit histone deacetylases and other cofactors. 3. An 
inactive chromatin environment as a result of chromatin remodeling does not allow transcription 
factors to bind. 
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First isolated in humans in 1992
69
, DNA Methyltransferases (DNMTs) are responsible for 
methylating the 5' carbon of cytosine when followed by a guanine (CpG)
70
.  DNMTs are able to 
methylate DNA both de novo, and in the hemi-methylated state which can occur after DNA 
replication.  DNMT1 preferentially methylates hemi-methylated substrate DNA, whereas 
DNMT3a and DNMT3b can methylate unmethylated and methylated DNA
71,72
.   DNMT1, 
termed the ‘maintenance’ methyltransferase, has shown a 10-40x preference for hemimethylated 
DNA substrates.    DNA methylation, catalyzed by the DNA methyltransferases, is the most 
common modification of eukaryotic DNA, and it is responsible for affecting gene regulation at 
many stages of development, and during adulthood
26,73
.  DNMT1 is required for embryonic 
development in mice, demonstrated by the arrested development of a DNMT1 deficient strain
74
.   
Other members of the DNMT family include DNMT3a and 3b, proteins responsible for genome 
wide de novo methylation
72
, a process  also crucial to early mouse development and 
gametogenesis.  DNMTs methylate and transcriptionally silence genes important for genomic 
stability, including imprinted genes, transposable elements, and genes on the inactivated X -
chromosome
75
.  DNMTs are also associated with many cancers
26,75,76
.  Inactivation of DNA-
damage response genes by aberrant promoter hypermethylation by DNMTs is closely linked to 
colorectal, breast, lung cancers, and glioma
76
.   
Ten-Eleven Translocation (TET) enzymes ('Erasers') 
Although there are many possible passive mechanisms by which methylated DNA may become 
demethylated, a family of enzymes identified as the Ten-eleven translocation methylcytosine 
dioxygenases (TETs)
77,78
 have been shown to be responsible for active demethylation of 
methylated cytosines in humans.  TET1 has dioxygenase activity that generates 5-mC derivatives 
including 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine 
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(5-CaC)
79
 (Fig. 4-3).  5-hmC is a key step in DNA demethylation, and may be passively depleted 
through DNA replication or through DNA-repair by thymine DNA glycosylase base-excision 
repair
79
.   
Chromatin Modifications 
Epigenetics also refers to the current state of histone post-translational modifications.  DNA-
wrapped histone proteins can be differentially acetylated or methylated at different loci, or at one 
locus in between individual cells or tissue types
43,80
.  By adding or relieving steric hindrance, 
modification of nucleosomal histone proteins modulates 'tightness' of the wrap of DNA around 
the histone core complex, and the transcriptional activity of a specific genomic location
80
.  The 
current model suggests acetylation of histone tails prevents DNA from wrapping tightly around 
the histone core protein, creating a transcriptionally active region, traditionally known as 
euchromatin
43,80,81
.  Methylation of histone proteins may be associated with repression or 
activation depending on which residue within the histone protein becomes modified
43
.   
Promoters of many tumor suppressor genes are occupied by MBD proteins in cancer cells 
The first report of an MBD protein associated with the methylated promoter of a gene in cancer 
was published in 2000
82
, where MBD2 was observed bound to p16 in colon cancer cell lines.  
Aberrantly high methylation levels in the promoter regions of many tumor suppressor genes, 
which leads to gene silencing, is now a widely accepted cancer mechanism
83
.  In addition to 
classifying high methylation levels in specific tumor suppressor genes in various cancer cell 
types, it is of inherent interest to describe the patterns and combinations of epigenetic factors that 
are responsible for translating epigenetic marks such as DNA methylation
84
. Knowledge of 
consistent MBD occupancy profiles for specific cancers could allow these MBD to serve as 
biomarkers as well as potential therapeutic targets
85
.  
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Fig 4-3. Cytosine methylation cycle.  Cytosine is methylated by DNA methyltransferases to 5-
methylcytosine (5-mC). 5-mC can be demethylated in a series of oxidation reactions by the Ten-
Eleven Translocation (TET) family proteins.   
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DAX-1 is differentially methylated in human cell lines 
In Chapter 3, the differential methylation of the CG rich region of the DAX-1 gene was 
described.   DAX-1 genomic DNA was analyzed for the methylation status in MCF7, MCF10F, 
and A549 cell lines.  Relative DAX-1 gene expression was found to be low in MCF7 breast 
cancer cells, with a 4.6 fold increase in MCF10F breast normal cells, and an over 400 fold 
increase in A549 lung cancer cells.  Methylation status was inversely proportional to gene 
expression, with A549 methylation low or non-detectable, MCF10F containing mixed 
methylated/unmethylated DNA, and MCF7 almost entirely methylated.  This phenomenon was 
also observed in four Mus musculus cell lines, including two embryonic stem cell lines, D3 and 
E14 (high DAX-1 expression), and two somatic cell lines that do not detectably express DAX-1 
(unpublished, George Tzertzinis, New England Biolabs).       
An analysis of the occupancy of two MBD proteins on the DAX-1 CpG Island 
To begin to investigate the mechanism bridging the hypermethylation of DAX-1 observed in 
MCF7 cells to reduced gene expression of DAX-1, chromatin immunoprecipitation (ChIP) 
assays were utilized.    In order to determine the factors that play a key role in regulating the 
methylation status of the DAX-1 gene, we sought to examine occupancy of two well classified 
epigenetic readers, MeCP2 and MBD1.   In addition, the presence of an epigenetic mark of 
active transcription, AcH3 was examined.   
MATERIALS AND METHODS 
Cell culture 
MCF7, MCF10F, and A549 cells were obtained from the American Type Culture Collection  
(ATCC).  MCF7 cells are known to be ER+ and responsive to estrogen, and were grown in 
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media lacking phenol red because of its potential endocrine disruptive actions.  Base DMEM/F-
12 media was supplemented with 10% FBS and other growth factors as described by ATCC.  
Cells were grown in T25 and T75 cell culture flasks with vented caps, and passaged 2-4 times 
per week, as described by ATCC recommended culture and subculture protocol.  Cells in T25 
flasks were grown with 3 ml media, and cells in T75 flasks grown with 12-15 ml media.  
Average cell number counted from a near confluent T75 flask was between 3-6 million cells, 
depending on cell line and growth characteristics.  Cell lineages were discarded after 20 
passages.     
Sonication Optimization 
Sonication conditions were optimized to produce DNA fragments of length 200-800bp in length.  
200µL of a 10ng/ul solution of human gDNA was used to optimize power level and sonication 
time with the Misonix S-4000 water bath sonicator in 1.5mL microtubes.  Starting at 50% power 
and 2 minutes sonication time, power and time were incremented up 5% and 30 seconds, 
respectively, until the desired fragment length was achieved.  Fragment length was analyzed by 
visualization on an ethidium bromide-stained 2% agarose gel and conditions that produced the 
greatest proportion of bands in the 200-800bp range were selected.  
 Chromatin Immunoprecipitation (ChIP) 
ChIP was conducted with the Epigentek (Farmingdale, NY) EpiQuick ChIP kit following the 
standard protocol provided by the manufacturer. Sonication of cross-linked chromatin was 
performed by water bath sonication using a Misonix S-4000 sonicator.  Sonication power was set 
to 73% for 5 minutes total, with 15s ON and 15s OFF cycling times.  Water in the sonication 
bath was kept ice-cold.  3 µg of antibody was used for each immunoprecipitation, where the 
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input material for each immunoprecipitation consisted of a pool of chromatin isolated from ~5 x 
10
5 
cells.  
ChIP Antibodies List 
anti-RNAPII, 
monoclonal 
Epigentek A-2032-050 
anti-AcH3, 
polyclonal 
Epigentek A-4021-025                                          
anti-MeCP2, 
polyclonal 
AbCam ab2828 
anti-IgG, 
polyclonal 
 
Epigentek P-2002 
anti-MBD1, 
polyclonal 
AbCam ab2846 
 
Note: anti-RNAPII antibody recognizes both phosphorylated and non-phosphorylated RNAPII. 
PCR Analysis 
Qualitative ChIP-PCR of DAX-1 was performed with DAX-1 primers designed to amplify a 
463bp genomic sequence including 330bp upstream of the transcriptional start site, as well as 
133bp of exon 1.  Forward primer sequence used for ChIP: 5’ AGATGCGAGGGTTCAATGGA 
3’, and the reverse primer sequence used was: 5’ CCCAGCACTGATCCACCA 3’. 
Amount of input and number of PCR cycles used for endpoint-PCR was optimized to produce 
the clearest and most reproducible visualization for each experiment.  Default PCR conditions 
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were as follows: 95°C denaturation step for 3 min (1 time), 95°C for 30s -> 60°C for 30s -> 72°C 
for 15s (35 times), 72°C for 4 min (1 time). 
RESULTS 
 Using the ChIP assay followed by PCR visualization, we  visualized the occupancy of DNA-
binding proteins on DAX-1. Three cell lines were analyzed for promoter occupancy by ChIP 
analysis: MCF7 breast cancer cells, MCF10F non-transformed breast cells, and A549 lung 
carcinoma cells.MeCP2 is associated with the DAX-1 promoter region in the MCF7 and 
MCF10F cells, but not in the A549 cells (Figure 4-4, lane 4).  Each of the cell lines examined 
demonstrate the presence of AcH3 on the DAX-1 promoter.     
In order to examine other factors that may also associate with the DAX-1 promoter, the presence 
of MBD1 was assayed.  MBD1 was strongly abundant on the DAX-1 promoter in MCF7 cells 
and weakly detected or undetectable in MCF10F and A549 cells, respectively(Fig. 4-5, lane 5).  
All three cell lines  examined showed  the presence of RNAPII on the DAX-1 5' region (Fig. 4-5, 
lane 3). 
DISCUSSION 
Based on the ChIP-PCR data,  we can propose simplified models of DAX-1 regulation by 
MeCP2 and MBD1.  The results of the ChIP assay suggest that MeCP2 is bound to the DAX-1 
promoter region (Tss -330 to +133) in MCF7 and MCF10F cell lines (Fig. 4-6).  The presence of 
MeCP2 on DAX-1 in MCF10F was originally unexpected.  MeCP2 is most often mentioned in 
the literature in association with aberrantly silenced tumor suppressor genes;however, in 
MCF10F MeCP2 may play a role in the normal function of the cell.  First, although methylated 
at a lower level in MCF10F, many individual CpG sites in the DAX-1 promoter are indeed  
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Fig 4-4. Endpoint-PCR of immunoprecipitated chromatin (lanes 2-4).  Input (lane 1) is a positive 
PCR control using a standardized portion of the total isolated chromatin.  MeCP2 bound to the 
DAX-1 promoter is immunoprecipitated from MCF7 and MCF10F, but not A549 chromatin. All 
three cell lines show evidence of an epigenetic mark associated with active transcription, 
acetylated histone H3 (lane 3).  IgG (lane 2) is included to demonstrate background binding of 
chromatin to a non-specific immunoglobulin.   
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Fig 4-5. Endpoint PCR of immunoprecipitated chromatin (lanes 2-5).  Input (lane 1) is a positive 
PCR control using a standardized portion of the total isolated chromatin.  MeCP2 bound to the 
DAX-1 promoter is immunoprecipitated from MCF7 and MCF10F chromatin, but not from 
A549 (lane 4(.  MBD1 bound to the DAX-1 promoter is immunoprecipitated strongly from 
MCF7 chromatin (lane 5), weakly from MCF10F chromatin, and not at all in A549.  RNAPII is 
immunoprecipitated from chromatin from all three cell lines (lane 3).  IgG is included to 
demonstrate background binding of chromatin to a nonspecific immunoglobulin (lane 2).       
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Fig 4-6. Proposed model of DAX-1 epigenetic regulation mechanism by MeCP2, based on ChIP-
PCR data. a) In MCF7, MeCP2 may be bound to DAX-1 in most cells in the population, leading 
to significantly reduced expression. b)  In MCF10F, MeCP2 may be bound to DAX-1 in few 
cells in the population, leading to an observed normal physiological level of DAX-1 expression. 
c) MeCP2 is not likely bound to the DAX-1 locus in A549 cells and the gene is openly 
transcribed. 
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methylated. MeCP2 only requires one methylated cytosine to bind to DNA, of which there are 
many in both MCF7 and MCF10F cell lines at the DAX-1 locus, but nearly zero in A549 cells. 
Thus, presence of a moderate amount of methylation of DAX-1 in MCF10F may allow MeCP2 
to play a role in regulating normal expression levels, but may be aberrantly affecting DAX-1 
regulation in MCF7 due to higher methylation and stronger repression. The data suggests that at 
physiologically normal levels for the breast tissue cell line, DAX-1 is epigenetically 
regulated;however, ChIP-PCR is not a sensitive enough assay to make a strong  conclusion about 
the differential roles of MeCP2 in the two differentially methylated environments.  It is possible 
that a slight difference in the levels of MeCP2 occupancy of the DAX-1 CpG island can lead to 
major differences in gene expression. A potential follow up experiment would be to knock down 
MeCP2 in both MCF7 and MCF10F cell lines and comparatively observe the effect on DAX-1 
expression. 
The results presented here also show MBD1 is bound to the DAX-1 promoter in MCF7 cells, and 
less so in MCF10F relative to the input controls for each cell line.  This result is validated by the 
presence of MBD1 protein in MCF7 cells
84
.  Compared to MeCP2, which only requires a single 
methylated CpG site to bind, MBD1 requires multiple methylated CpG sites in order to bind to 
DNA
63.64
.  It is possible that MBD1 recognition sequences occur less often in the less-methylated 
DAX-1 gene in MCF10F, leading to lesser or no repression activity of MBD1 on the DAX-1 
promoter in MCF10F (Fig. 4-7).    
The results shown here lay a foundation for further research into the mechanism of epigenetic 
regulation of DAX-1.  Future experiments could include a large scale screen of promoter 
occupancy of epigenetic factors and marks for which validated antibodies are available, in search  
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Fig 4-7.  Proposed model of DAX-1 epigenetic regulation by MBD1, based on ChIP-PCR 
results. a) The CpG methylation status of the DAX-1 promoter in MCF10F cells is mixed (see. 
part II, DAX-1 Methylation Status). MBD1 must recognize sequences of multiple methylated 
CpG sites which may be less present or absent in the DAX-1 promoter region in MCF10F cells. 
b) The CpG methylation status of the DAX-1 promoter in MCF7 cells is highly methylated (part 
II). MBD1 may have more potential binding sites within the highly methylated DAX-1 promoter 
region of MCF7 cells, leading to repression of DAX-1 transcription.        
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of one or several factors that appear on DAX-1 in MCF7 but  absent in MCF10F.  It may be 
especially useful to probe for the presence of epigenetic 'erasers' on the DAX-1 promoter in the 
unmethylated environment of the A549 cell line, compared to MCF7 and MCF10F cells.   
Additionally, more quantitative methods to assay promoter occupation could be utilized.  With 
further optimization, it may be possible to quantitatively assess the enrichment of epigenetic 
factors on the DAX-1 promoter using a stringent quantitative real-time PCR protocol or by high 
throughput methods such as ChIP-seq.  High throughput analysis of immunoprecipitated 
chromatin, although not specifically targeted at DAX-1, may give quantitative insight due to the 
normalization of sample by ligation of adapter oligonucleotides in the library preparation phase 
of deep sequencing, and use of non-gene-specific primers.  ChIP-seq would be a valuable tool 
for future experiments involving quantification of epigenetic factors on the DAX-1 promoter 
between cell lines.  Because ChIP-seq uses whole-genome sequencing, it would also allow a 
broader investigation of DAX-1 regulation pathways such as observing the epigenetic status of 
DAX-1 target genes. 
In summary, the occupancy of the DAX-1 promoter by two well classified epigenetic readers 
was observed, showing a striking difference between MCF7 and A549 cells, and a potentially 
meaningful difference between MCF7 and MCF10F cells.  Further investigation into the 
promoter occupancy of DAX-1 is needed to determine the role of aberrant DAX-1 expression in 
two tumorigenic cell lines MCF7 and A549.   
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CHAPTER 5:  SUMMARY 
DAX-1 is an unusual nuclear hormone receptor that lacks the ability to directly bind to DNA and 
has no known ligand.  DAX-1 is important in the development of steroidogenic tissues, sex 
determination, and has a global function as a negative coregulator of other nuclear hormone 
receptors such as LRH-1 and ER-α. DAX-1 may be implicated in cancer cells where aberrant 
levels of DAX-1 lead to misregulation of nuclear hormone receptor that control cell growth. The 
gene expression of DAX-1 was quantified in two common cancer cell lines, MCF7 (breast) and 
A549 (lung), and compared to a normal breast tissue cell line MCF10F.  DAX-1 expression was 
found to be low in MCF7 cells and very high in A549 cells. To test the hypothesis that DAX-1 
expression is regulated by epigenetic mechanisms, the CpG content of the DAX-1 gene was 
analyzed and found to contain a CpG-island in the 5' promoter region and extending into exon 1. 
The DNA methylation status of the DAX-1 CpG island in MCF7,MCF10F, and A549 cells was 
analyzed by a methylation sensitive restriction digest, and further by bisulfite sequencing to 
obtain an in-depth view of the methylation status of many CpG sites.  The DAX-1 CpG island 
was found to be very methylated in MCF7 cells, mixed methylated in MCF10F cells, and  
unmethylated in A549 cells. To investigate the possible effects of differential methylation of 
DAX-1, the chromatin immunoprecipitation assay was used to observe the occupancy of two 
well-classified epigenetic readers, MeCP2 and MBD1, on the DAX-1 promoter region. MeCP2 
was observed bound to the DAX-1 promoter in MCF7 and MCF10F cells, but absent in A549 
cells. MBD1 was observed strongly bound to the DAX-1 promoter in MCF7 cells, weakly bound 
in MCF10F cells, and absent in A549 cells. The differential occupancy of epigenetic readers 
between the two cancer cell lines suggests an epigenetic cause for aberrant DAX-1 expression 
levels, a potential contributor of the tumorigenic phenotype.     
78 
 
To validate these findings outside of a cell line model system, future research into the epigenetic 
regulation of DAX-1 should include methylation analysis of breast and lung cancer tissue from 
human patients. Additionally, a large scale screen of the occupancy of epigenetic writers and 
erasers on the DAX-1 CpG island should be performed. With this knowledge, knockouts of 
epigenetic factors in cancer cell lines could be created, and the expression and methylation of 
DAX-1 could be analyzed and compared to a potential change in tumorigenicity of the cells. The 
end goal of this research is to determine if aberrant epigenetic regulation of DAX-1 in cancer or 
other disease environments may contribute to disease phenotypes, giving the scientific 
community knowledge that could be used to pursue new avenues of treatment.  
Because DAX-1 has no known ligand, and a diminished binding pocket, attempting to design a 
synthetic modulator of DAX-1 would be impractical. Instead, future researchers and 
bioengineers could use promising new technologies such as gene therapy or gene editing to 
regulate the levels of DAX-1 in abnormal environments with the hope of restoring normal 
phentoypes. In addition, the future may hold technology allowing the epigenetic status of  small 
genomic regions in vivo to be programmable, allowing scientists to fine tune gene expression 
pathways by selectively adding or removing methylation.  
In summary, the results presented here represent a base of information about the epigenetic 
regulation of DAX-1 that can be used to justify and guide further research into the epigenetics of 
nuclear hormone receptors, and could provide a new avenue of development for cancer 
medicine. 
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